OmniAb (OABI) Assets Average (2021 - 2026)
OmniAb (OABI) posted quarterly Assets Average of $297.3 million for Q1 2026, down 5.88% year-over-year from $315.9 million in Q1 2025, and down 2.63% quarter-over-quarter from $305.3 million in Q4 2025.
Analysis
OmniAb (OABI) Assets Average (2021 - 2026) Analysis & Trends
OmniAb (OABI) has reported Assets Average for 6 consecutive years, with $297.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 5.88% year-over-year to $297.3 million; the TTM figure through Mar 2026 stood at $297.3 million (down 5.88% YoY), while the FY2025 annual figure was $313.2 million, down 10.6% from the prior year.
- Assets Average slipped to $297.3 million in Q1 2026 per OABI's latest filing, from $305.3 million in the prior quarter.
- Across five years, Assets Average topped out at $417.1 million in Q1 2023 and bottomed at $236.8 million in Q2 2022.
- Historically, Assets Average has averaged $328.0 million across 5 years, with a median of $328.6 million in 2024.
- Annual changes were most pronounced in 2022 — Assets Average surged 99.64% — and 2024, when it declined 16.08%.
- OmniAb's Assets Average stood at $329.4 million in 2022, then gained by 16.41% to $383.5 million in 2023, then dropped by 14.32% to $328.6 million in 2024, then retreated by 7.08% to $305.3 million in 2025, then dropped by 2.63% to $297.3 million in 2026.
- Business Quant data shows OABI's Assets Average at $297.3 million in Q1 2026, $305.3 million in Q4 2025, and $302.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 2.09 Bn |
| 10 | OmniAb | 564.12 Mn | 512.13 Mn | 12.81 Mn | 291.95 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 291.95 Mn |
| Mar 31, 2026 | 297.28 Mn |
| Dec 31, 2025 | 305.30 Mn |
| Sep 30, 2025 | 302.68 Mn |
| Jun 30, 2025 | 300.93 Mn |
| Mar 31, 2025 | 315.87 Mn |
| Dec 31, 2024 | 328.56 Mn |
| Sep 30, 2024 | 334.41 Mn |
| Jun 30, 2024 | 344.91 Mn |
| Mar 31, 2024 | 363.89 Mn |
| Dec 31, 2023 | 383.47 Mn |
| Sep 30, 2023 | 398.47 Mn |
| Jun 30, 2023 | 409.14 Mn |
| Mar 31, 2023 | 417.13 Mn |
| Dec 31, 2022 | 329.41 Mn |
| Sep 30, 2022 | 237.20 Mn |
| Jun 30, 2022 | 236.85 Mn |
| Mar 31, 2022 | 270.68 Mn |
| Dec 31, 2021 | 270.73 Mn |
| Sep 30, 2021 | 118.81 Mn |